PhD Scientific Days 2022

Molecular Sciences II.

Fluvoxamine Reduces Fibrotic Changes in Trabecular Meshwork Cells

Előadó neve

Medveczki, Timea

Előadó munkahelye

Semmelweis University 1st Department of Pediatrics

Előadó telefonszáma

+36305391772

Előadó e-mail címe

medveczki.timea@gmail.com

Az előadás címe

Fluvoxamine Reduces Fibrotic Changes in Trabecular Meshwork Cells

Szerző(k) neve és munkahelye

Timea Medveczki 1,2, Minh N. Tran 1,2, Balazs Besztercei 3, Illes Kovacs 4,5, Laszlo Orfi 6, Xavier Gasull 7, Attila J. Szabo 2, Judit Hodrea 1,2, Andrea Fekete 1,2

1 MTA-SE Lendület “Momentum” Diabetes Research Group, Semmelweis University, Budapest
2 1st Department of Pediatrics, MTA Centre of Excellence, Semmelweis University, Budapest
3 Institute of Clinical Experimental Research, Semmelweis University, Budapest
4 Department of Ophthalmology, Semmelweis University, Budapest
5 Department of Ophthalmology, Weill Cornell Medical College, New York, NY
6 Department of Pharmaceutical Chemistry, Semmelweis University, Budapest
7 Department of Biomedicine, Institute of Neurosciences, University of Barcelona, Barcelona

Bemutatás módja

Szóbeli

Szekció

Molecular Sciences II.

Language of the presentation

Hungarian

Preferred session

Molecular Sciences

Összefoglaló szövege

Introduction
Trabecular meshwork (TM) is the main pathway for aqueous humor drainage from the eye. The fibrotic-like remodeling of the actin cytoskeleton in TM cells results in altered stiffness and impaired outflow which are the primary cause of increased intraocular pressure (IOP) leading to glaucoma. Thus, cytoskeletal-disrupting drugs could be a novel therapeutic approach to lower IOP. Recently, we proved that fluvoxamine (FLU), a specific Sigma-1 receptor agonist is antifibrotic in the kidney.

Aims
We investigated whether FLU is effective in the prevention of cytoskeletal rearrangement and in vitro TM fibrosis in primary mouse- (MsTM) and non-glaucomatous human TM cells (HTM5).

Methods
Immunocytochemistry and Western blot were used to detect S1R on HTM5 and on MsTM cells. Primary MsTM cells from wild type (WT) and S1R knock-out (KO) mice and HTM5 cells were treated for 24h with 20 ng/mL platelet-derived growth factor (PDGF) combined with 10 µM of FLU. Cell proliferation was determined by thiazolyl blue tetrazolium bromide assay and cell migration was measured by scratch assay, and F-actin was visualized by phalloidin staining and detected with fluorescent microscope.

Results
S1R is present both in primary MsTM and HTM5 cells and is localized in the endoplasmic reticulum. Cell proliferation, migration and cytoskeletal rearrangement were induced by PDGF. FLU treatment ameliorated or even prevented the PDGF induced changes in all assays. Furthermore, upon PDGF treatment the integrated density of phalloidin staining increased with 19.73% in primary KO MsTM cells compared to WT and the formation of F-actin bundles and actin clumps was more pronounced in the absence of S1R suggesting its protective role in TM fibrosis.

Conclusions
FLU effectively reduces profibrotic factor-induced cytoskeletal rearrangement and cell proliferation of TM cells. Therefore one can speculate that it might lead to lower outflow resistance also in animals and it could be an IOP-lowering drug candidate for glaucoma.

Funding
OTKA- K135398, LP2021-3/2021, TKP2021-EGA-24, 2020-4.1.1.-TKP2020-6183169273

medveczki.timea@gmail.com
Semmelweis University, Károly Rácz Doctoral School of Clinical Medicine
Supervisors: Dr. Andrea Fekete, Dr. Judit Hodrea

University and Doctoral School

Semmelweis University, Károly Rácz Doctoral School of Clinical Medicine

Supervisor

Dr. Andrea Fekete, Dr. Judit Hodrea

Publication of my abstract

I give consent to the publication of my abstract on the website of the congress.

Kind

Szabad

Status

elfogadva

Accepted presentation method

szóbeli

Előadás fájl jóváhagyás

nem rendelkezett róla

Előadó

6840

Start

15:00

End

15:15

Authors (legacy)

Timea Medveczki 1,2, Minh N. Tran 1,2, Balazs Besztercei 3, Illes Kovacs 4,5, Laszlo Orfi 6, Xavier Gasull 7, Attila J. Szabo 2, Judit Hodrea 1,2, Andrea Fekete 1,2

1 MTA-SE Lendület “Momentum” Diabetes Research Group, Semmelweis University, Budapest
2 1st Department of Pediatrics, MTA Centre of Excellence, Semmelweis University, Budapest
3 Institute of Clinical Experimental Research, Semmelweis University, Budapest
4 Department of Ophthalmology, Semmelweis University, Budapest
5 Department of Ophthalmology, Weill Cornell Medical College, New York, NY
6 Department of Pharmaceutical Chemistry, Semmelweis University, Budapest
7 Department of Biomedicine, Institute of Neurosciences, University of Barcelona, Barcelona